Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review
Sign Up to like & getrecommendations! Published in 2021 at "Advances in Therapy"
DOI: 10.1007/s12325-021-01989-z
Abstract: Despite the availability of established treatments, heart failure (HF) is associated with a poor prognosis and its management is suboptimal, highlighting the need for new options for treatment and prevention. Patients with type 2 diabetes… read more here.
Keywords: type diabetes; sglt 2is; heart; treatment ... See more keywords
Comparison of glucagons like peptide-1 receptor agonists and dipeptidyl peptide-4 inhibitors regarding cardiovascular safety and mortality in type 2 diabetes mellitus: A network meta-analysis.
Sign Up to like & getrecommendations! Published in 2020 at "Primary care diabetes"
DOI: 10.1016/j.pcd.2020.08.012
Abstract: AIM The effects of dipeptidyl peptide-4 inhibitors (DPP-4is) and sodium-glucose cotransporter-2 inhibitors (SGLT-2is) on type 2 diabetes mellitus (T2DM) on cardiovascular events and all-cause mortality were compared. METHODS The literature on DPP-4is and SGLT-2is treatment… read more here.
Keywords: peptide; dpp 4is; mortality; sglt 2is ... See more keywords
Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists
Sign Up to like & getrecommendations! Published in 2017 at "Expert Review of Clinical Pharmacology"
DOI: 10.1080/17512433.2017.1318061
Abstract: ABSTRACT Introduction: Both sodium-glucose co-transporter-2 inhibitors (SGLT-2Is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been consistently found to lower blood glucose, body weight and systolic blood pressure (SBP) in patients with type 2 diabetes mellitus… read more here.
Keywords: glp 1ras; sglt 2is; canagliflozin 300; receptor agonists ... See more keywords
Sodium-glucose transporter-2 inhibitors: safety and efficacy in patients with peripheral artery disease.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of cardiovascular pharmacology"
DOI: 10.1097/fjc.0000000000001703
Abstract: The objective of this review is to assess the safety and efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT-2is) in patients with peripheral arterial disease (PAD). A literature search of PubMed and EMBASE databases (through March 2025)… read more here.
Keywords: sglt 2is; sodium glucose; safety efficacy; pad ... See more keywords
Amelioration of endothelial dysfunction by sodium glucose co‐transporter 2 inhibitors: pieces of the puzzle explaining their cardiovascular protection
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Pharmacology"
DOI: 10.1111/bph.15850
Abstract: Sodium glucose co‐transporter 2 inhibitors (SGLT‐2is) improve cardiovascular outcomes in both diabetic and non‐diabetic patients. Preclinical studies suggest that SGLT‐2is directly affect endothelial function in a glucose‐independent manner. The effects of SGLT‐2is include decreased oxidative… read more here.
Keywords: sglt 2is; glucose transporter; sodium; transporter inhibitors ... See more keywords
Do GLP‐1RAs and SGLT‐2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta‐analysis
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes"
DOI: 10.1111/dom.13805
Abstract: While recent cardiovascular safety trials (CVST) concerning newer diabetes medications included mostly white participants, results are being generalized to all races in recent guidelines. This raises a controversial question regarding the appropriateness of applying CVST… read more here.
Keywords: black patients; patients type; glp 1ras; 1ras sglt ... See more keywords
Sodium‐glucose co‐transporter‐2 inhibitors and protection from cardiovascular death: Is it all about heart failure?
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes"
DOI: 10.1111/dom.14444
Abstract: To the Editor: The results of the EMPA-REG Outcome trial heralded the cardiovascular (CV) relevance of sodium-glucose co-transporter-2 inhibitors (SGLT-2is), showing an unprecedented reduction of CV death by 38% over standard of care. Then, results… read more here.
Keywords: death; analysis; sglt 2is; empa reg ... See more keywords
Secular trends in the utility of SGLT-2 inhibitors in heart failure patients with type 2 diabetes mellitus across Metro South Health hospitals in South-East Queensland.
Sign Up to like & getrecommendations! Published in 2022 at "Internal medicine journal"
DOI: 10.1111/imj.15993
Abstract: BACKGROUND The 2018 Australian Heart Failure (HF) guidelines strongly recommended commencing sodium-glucose co-transporter-2 inhibitors (SGLT-2is) in HF patients with type 2 diabetes mellitus (T2DM). The uptake of SGLT-2is for HF patients with T2DM in our… read more here.
Keywords: patients type; sglt 2is; heart failure; health ... See more keywords
Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "BMJ Open"
DOI: 10.1136/bmjopen-2022-061807
Abstract: Objective To compare the efficacy and safety between and within glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT-2is) in overweight or obese adults with or without diabetes mellitus. Methods PubMed, ISI Web… read more here.
Keywords: sglt 2is; safety; overweight obese; efficacy ... See more keywords
Effect of sodium glucose cotransporter-2 inhibitors (SGLT-2is) on the clinical outcomes of patients with diabetic atrial fibrillation
Sign Up to like & getrecommendations! Published in 2024 at "BMC Cardiovascular Disorders"
DOI: 10.1186/s12872-024-04454-1
Abstract: Diabetes mellitus (DM) and atrial Fibrillation (AF) are among the most common health issues. They are responsible for the highest rates of morbidity and mortality. The importance of sodium glucose cotransporter-2 inhibitors (SGLT-2is) in treating… read more here.
Keywords: inhibitors sglt; glucose cotransporter; cotransporter inhibitors; sglt 2is ... See more keywords
Exploring the mortality and cardiovascular outcomes with SGLT-2 inhibitors in patients with T2DM at dialysis commencement: a health global federated network analysis
Sign Up to like & getrecommendations! Published in 2024 at "Cardiovascular Diabetology"
DOI: 10.1186/s12933-024-02424-7
Abstract: Sodium-glucose cotransporter 2 inhibitors (SGLT-2is) have demonstrated associations with lowering cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM). However, the impact of SGLT-2is on individuals at dialysis commencement remains unclear. The aim of… read more here.
Keywords: patients t2dm; sglt 2is; mortality; dialysis ... See more keywords